Loading...
•
Dec 31, 2024
ANI Pharmaceuticals Q4 2024 Earnings Report
ANI Pharmaceuticals reported record fourth quarter financial results, driven by strong performance in Rare Disease and Generics segments and the acquisition of Alimera Sciences.
Key Takeaways
ANI Pharmaceuticals reported record Q4 2024 financial results, with a 44.8% increase in total net revenues to $190.6 million. The company's Rare Disease segment, including Cortrophin Gel, ILUVIEN, and YUTIQ, significantly contributed to this growth. Adjusted non-GAAP EBITDA increased by 65.7% to $50.0 million, and adjusted non-GAAP diluted earnings per share reached $1.63.
Total net revenues reached a record $190.6 million, a 44.8% year-over-year increase.
Rare Disease segment revenues totaled $87.0 million, including record Cortrophin Gel revenues of $59.4 million.
Adjusted non-GAAP EBITDA reached a record $50.0 million, a 65.7% year-over-year increase.
The company raised its 2025 guidance for net revenues to $756.0 million - $776.0 million and adjusted non-GAAP EBITDA to $190.0 million - $200.0 million.
Forward Guidance
ANI Pharmaceuticals raised its full year 2025 guidance, expecting increased net revenues and adjusted non-GAAP EBITDA.
Positive Outlook
- Net Revenue (Total Company) expected between $756 million - $776 million
- Cortrophin Gel Net Revenue expected between $265 million - $274 million
- ILUVIEN and YUTIQ Net Revenue expected between $97 million - $103 million
- Adjusted Non-GAAP EBITDA expected between $190 million - $200 million
- Adjusted Non-GAAP Diluted EPS expected between $6.12 - $6.49
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...